Hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), also known as familial amyloid polyneuropathy (FAP), is a rare genetic disease characterized by damage to the peripheral nerves found outside the brain and spinal cord. It is typically…
Problems associated with nerve damage are the main symptoms of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN). However, because the disease can affect multiple organs and systems in the body, including the heart, clinical manifestations…
Hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) diagnosis typically involves identifying hATTR-PN symptoms and performing specialized testing to confirm the disease’s presence. Inherited mutations in the TTR gene cause hATTR-PN by destabilizing and changing the…
Medications, clinical monitoring, and symptom management can all play a role in hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) treatment. Also known as familial amyloid polyneuropathy, hATTR-PN is a genetic condition marked by polyneuropathy, or…
Hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), also known as familial amyloid polyneuropathy (FAP), is a form of familial amyloidosis caused by mutations in the TTR gene, which contains instructions for cells to produce a…
Latest News & Community Perspectives
A blood test commonly used to help diagnose Alzheimer’s disease may also identify people with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), characterized by damage to the peripheral nerves found outside the brain and spinal…
Six months of treatment with Amvuttra (vutrisiran) appears to maintain or slightly improve clinical status and quality of life among adults with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), according to a small real-world…
Hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) was a common clinical manifestation among people carrying a mutation in the TTR gene called p.Ala117Ser, according to a study conducted in Thailand. Similar to findings from other…
Homes and landmarks across the U.S. and other countries will once again light up in red throughout March for Amyloidosis Awareness Month as the Amyloidosis Foundation reprises its annual “Light the Night for Amyloidosis”…
An easily accessible diagnostic test called pain-related evoked potentials with concentric electrodes (PrEP-CE) may help detect the onset of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), according to a small study in Brazil. Changes in…
Overactivation of Rac1, a protein that regulates components of a cell’s skeleton, may drive early nerve damage in hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), according to new data from a preclinical study. The research…
Minimally invasive skin biopsies may be used to diagnose transthyretin amyloidosis and guide treatment in people with the rare progressive disease, according to the findings of a new study from Switzerland. A team of scientists…
The U.S. Food and Drug Administration (FDA) has lifted a clinical hold on a Phase 3 clinical trial testing the investigational gene-editing therapy, nexiguran ziclumeran (nex-z), in adults with hereditary transthyretin amyloidosis with polyneuropathy…
More than half of adults with hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM), a condition marked by heart damage, also have multi-nerve damage, according to a new study from the University of Toronto. The findings…
MRI scans detect brain changes in adults with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) before symptoms appear, according to a study. While these changes were not associated with cognitive problems in early-stage hATTR-PN patients…